Cannabis in Adults with Cancer
Publication Date: March 12, 2024
Key Points
Key Points
- Cannabis and/or cannabinoid access and use by adults with cancer has outpaced the science supporting their clinical use.
- This guideline provides strategies for open, nonjudgmental communication between adults with cancer and clinicians about the use of cannabis and cannabinoids.
- Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial.
- Cannabis and/or cannabinoids may improve refractory, chemotherapy-induced nausea and vomiting (CINV) when added to guideline-concordant antiemetic regimens.
- Whether cannabis and/or cannabinoids can improve other supportive care outcomes remains uncertain.
Treatment
...reatment...
...mmunication and Education...
....1Health systems and clinicians, in partnershi...
...ommendation 1.2Given the high prev...
...on 1.3When adults with cancer use cannabis a...
Cancer Trea...
...mendation 2.1Clinicians should recomm...
...tion 2.2Clinicians should recommen...
...ent-related Toxicity, Symptoms, and...
...ecommendation 3.1...
...abinol and nabilone] (EB, , M, Weak)...
[for 1:1 THC:CBD extract] (EB, , L, Weak)34...
...ndation 3.2Outside of a clinical tri...
...3.3Evidence remains insufficient to recomme...
...1. Taking an In-depth History of Ca...
...2. Summary of Recommendations Pertaining to...
...le 3. General Safety AwarenessHaving tro...
Figure 1. Endocannabinoid S...
...eves that cancer clinical trials are vital to i...